Evaluation of tenapanor administration in hemodialysis patients on laxative therapy

Evaluation of tenapanor administration in hemodialysis patients on laxative therapy - Evaluation of tenapanor administration in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057310

Enrollment

Registered

2025-06-30

Start date

2024-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patient taking laxatives for constipation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients on regular laxative therapy

Exclusion criteria

Exclusion criteria: Patients who have previously taken tenapanor

Design outcomes

Primary

Measure	Time frame
Reduction or discontinuation of laxatives for hemodialysis patients	—

Secondary

Measure	Time frame
Discontinuation of stimulant laxatives in hemodialysis patients Compliance rate with new guidelines for serum phosphorus	—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp+81-776-21-1277

Outcome results